Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Zagozdzon

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
International Journal of Molecular Medicine|April 15, 1999
Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review)J Golab, R Zagozdzon
International Journal of Oncology|February 15, 2001
Immunomodulation by anticancer chemotherapy: more is not always better (review)R Zagozdzon, J Golab
Przeglad Lekarski|November 11, 1999
[Autoimmune liver diseases. Part I]J Ziółkowski, R Zagozdzon, L Paczek
Przeglad Lekarski|November 11, 1999
[Autoimmune liver diseases. Part II]R Zagozdzon, J Ziółkowski, L Paczek
European Journal of Cancer (Oxford, England : 1990)|June 26, 1998
Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in miceW Feleszko, R Zagozdzon, J Gołab, et al.
International Journal of Molecular Medicine|November 24, 1999
Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model in vivoR Zagozdzon, J Golab, K Mucha, et al.
Cancer Letters|February 5, 2000
The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide productionR Zagozdzon, A Giermasz, J Gołab, et al.
Anticancer Research|March 12, 1998
Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma modelR Zagozdzon, T Stokłosa, J Gołab, et al.
Oncology Reports|December 22, 1999
Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivoJ Golab, R Zagozdzon, K Kozar, et al.
International Journal of Cancer|August 4, 1998
Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatinR Zagozdzon, J Gołab, T Stokłosa, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
International Journal of Molecular Medicine|April 15, 1999
Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review)J Golab, R Zagozdzon
International Journal of Oncology|February 15, 2001
Immunomodulation by anticancer chemotherapy: more is not always better (review)R Zagozdzon, J Golab
Przeglad Lekarski|November 11, 1999
[Autoimmune liver diseases. Part I]J Ziółkowski, R Zagozdzon, L Paczek
Przeglad Lekarski|November 11, 1999
[Autoimmune liver diseases. Part II]R Zagozdzon, J Ziółkowski, L Paczek
European Journal of Cancer (Oxford, England : 1990)|June 26, 1998
Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in miceW Feleszko, R Zagozdzon, J Gołab, et al.
International Journal of Molecular Medicine|November 24, 1999
Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model in vivoR Zagozdzon, J Golab, K Mucha, et al.
Cancer Letters|February 5, 2000
The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide productionR Zagozdzon, A Giermasz, J Gołab, et al.
Anticancer Research|March 12, 1998
Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma modelR Zagozdzon, T Stokłosa, J Gołab, et al.
Oncology Reports|December 22, 1999
Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivoJ Golab, R Zagozdzon, K Kozar, et al.
International Journal of Cancer|August 4, 1998
Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatinR Zagozdzon, J Gołab, T Stokłosa, et al.
Pageof 3